Merck & Co. Chief Executive Ken Frazier said a rule to base the price the U.S. government pays for some prescription drugs in Medicare on lower prices in other countries would face legal challenges if adopted.
Klick Health research found Google Assistant’s comprehension of the most commonly dispensed medication names in the U.S. was, on average, almost twice as accurate as Alexa and Siri’s.
Genentech announced positive topline results from the Phase III PEMPHIX trial evaluating Rituxan (rituximab) compared to the immunosuppressant drug MMF in patients with pemphigus vulgaris.
A Canadian advisory council studying prescription drug coverage said the federal government should create a universal, single-payer public pharmacare system, and warned that the current framework requires significant reforms.
Merck & Co. Inc.’s blockbuster cancer drug Keytruda won approval from the U.S. FDA to treat a type of head and neck cancer.
As concerns over the price of prescription medicine continue to make headlines as the country barrels toward another election, a new study from the Scripps Research bolsters an argument touted by the pharmaceutical industry over the rebate system.
Five-Year Survival Observed In Longest Follow-Up Of Advanced Melanoma Patients Treated With Opdivo-Yervoy Combination
Bristol-Myers Squibb Company announced updated results from studies evaluating Opdivo (nivolumab) and Yervoy (ipilimumab), alone or in combination, in patients with advanced or metastatic melanoma.
Nearly a quarter of patients who received Merck & Co.’s immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a major medical meeting.
Novartis released data showing sharply improved overall survival rates for the breast cancer drug Kisqali, which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizer’s blockbuster Ibrance.
The Canadian province of British Columbia said its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars.